Detalhe da pesquisa
1.
Tucidinostat Plus Exemestane as a Neoadjuvant in Early-Stage, Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer.
Oncologist;
29(6): e763-e770, 2024 Jun 03.
Artigo
em Inglês
| MEDLINE
| ID: mdl-38459836
2.
STAT3 and PD-L1 are negatively correlated with ATM and have impact on the prognosis of triple-negative breast cancer patients with low ATM expression.
Breast Cancer Res Treat;
196(1): 45-56, 2022 Nov.
Artigo
em Inglês
| MEDLINE
| ID: mdl-36056297
3.
Analysis of Clinicopathological Characteristics and Prognosis of Carcinosarcoma of the Breast.
Breast J;
2022: 3614979, 2022.
Artigo
em Inglês
| MEDLINE
| ID: mdl-35865143
4.
Effects of tumor-infiltrating lymphocytes on nonresponse rate of neoadjuvant chemotherapy in patients with invasive breast cancer.
Sci Rep;
13(1): 9256, 2023 06 07.
Artigo
em Inglês
| MEDLINE
| ID: mdl-37286786
5.
Genetic polymorphisms in CDH1 are associated with endometrial carcinoma susceptibility among Chinese Han women.
Oncol Lett;
16(5): 6868-6878, 2018 Nov.
Artigo
em Inglês
| MEDLINE
| ID: mdl-30405831
6.
Genetic Polymorphisms of TGFB1, TGFBR1, SNAI1 and TWIST1 Are Associated with Endometrial Cancer Susceptibility in Chinese Han Women.
PLoS One;
11(5): e0155270, 2016.
Artigo
em Inglês
| MEDLINE
| ID: mdl-27171242
7.
Association of Genetic Polymorphisms in CDH1 and CTNNB1 with Breast Cancer Susceptibility and Patients' Prognosis among Chinese Han Women.
PLoS One;
10(8): e0135865, 2015.
Artigo
em Inglês
| MEDLINE
| ID: mdl-26285011